NCT03404167View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 2, 2018

Primary Completion Date

March 2, 2018

Study Completion Date

March 2, 2018

Conditions
Gonorrhoea
Interventions
DRUG

AZD0914

Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent

Trial Locations (1)

66211-1553

Quintiles Phase I Services - Overland Park, Overland Park

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03404167 - A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers | Biotech Hunter | Biotech Hunter